SGLT2 inhibitor role in cardio-metabolic-renal diseases: a narrative review of recent evidence and their pharmacological, clinical and economic implications
Abstract
Cardio-metabolic-renal (CMR) conditions, including type 2 diabetes mellitus, cardiovascular disease and chronic kidney disease, represent some of the most pressing public health challenges of the 21st century. In recent years, sodium-glucose co-transporter 2 (SGLT2) inhibitors (SGLT2is) have emerged as promising therapeutic agents across these interconnected disease areas. In Europe, the four currently approved SGLT2is for the treatment of type 2 diabetes mellitus - dapagliflozin, empagliflozin, canagliflozin and ertugliflozin - all have demonstrated cardiovascular and renal benefits in large cardiovascular outcomes trials. Notably, empagliflozin and dapagliflozin have also received approval for the treatment of heart failure and chronic kidney disease. This narrative review provides an overview of the role of SGLT2is in the management of CMR diseases. Overall, SGLT2is have demonstrated consistent cardiovascular safety and clinically meaningful benefits in selected outcomes across CMR conditions, with variations amongst individual agents reflecting differences in trial populations, study design and approved indications. This review summarizes current evidence to support individualized therapeutic decision-making rather than comparative positioning within the class.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.